Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

Changes in Phospholipid Content and Myocardial Calcium-Independent Phospholipase A2 Activity during Chronic Anthracycline Administration

Jane McHowat, Luther M. Swift, Kimberly N. Crown and Narine A. Sarvazyan
Journal of Pharmacology and Experimental Therapeutics November 2004, 311 (2) 736-741; DOI: https://doi.org/10.1124/jpet.104.069419
Jane McHowat
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luther M. Swift
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly N. Crown
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Narine A. Sarvazyan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Despite numerous investigations, the causes underlying anthracycline cardiomyopathy are yet to be established. We have recently reported that acute treatment with anthracyclines inhibits membrane-associated calcium-independent phospholipase A2 (iPLA2) activity both in vitro and in vivo. This study presents data that iPLA2 activity is also suppressed during chronic drug administration. Adult Sprague-Dawley rats were given weekly 1 mg/kg i.v. injections of doxorubicin for a total of 8 weeks. One week after the last injection, the animals were sacrificed, and heart tissue was assessed for phospholipid content and iPLA2 activity. Membrane-associated iPLA2 activity in the myocardium of doxorubicin-treated animals was 40% lower than that in control hearts. In addition, doxorubicin treatment resulted in significant alterations in the distribution of fatty acyl moieties esterified to the sn-2 position of choline glycerophospholipids. The ethanolamine species remained unaffected. Elevation in the amount of arachidonate and linoleate esterified to the sn-2 position of choline plasmalogens was consistent with the hypothesis that iPLA2 displays selectivity for plasmalogen phospholipids; therefore, enzyme inhibition may affect hydrolysis of these phospholipid subclasses. Notably, the changes in phospholipid content occurred at a low cumulative dose of 8 mg/kg at which appearance of structural lesions was minimal. Therefore, these alterations seem to be both specific and early signs of cardiomyocyte pathology. The results support our hypothesis that myocardial iPLA2 inhibition may be one of the steps that leads to the functional and structural changes associated with chronic anthracycline treatment.

Footnotes

  • This work was supported by National Institutes of Health Grants HL68588 (to J.M.) and HL62419 (to N.A.S.).

  • doi:10.1124/jpet.104.069419.

  • ABBREVIATIONS: iPLA2, calcium-independent phospholipase A2; AIPI, anthracycline-induced phospholipase A2 inhibition; PLA2, phospholipase A2; HPLC, high-performance liquid chromatography; CGP, choline glycerophospholipid; EGP, ethanolamine glycerophospholipid; PVDF, polyvinylidene difluoride; cis-UFA PLD, cis-unsaturated fatty acid-sensitive form of phospholipase D.

    • Received April 3, 2004.
    • Accepted August 4, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 311 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 311, Issue 2
1 Nov 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Changes in Phospholipid Content and Myocardial Calcium-Independent Phospholipase A2 Activity during Chronic Anthracycline Administration
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCARDIOVASCULAR

Changes in Phospholipid Content and Myocardial Calcium-Independent Phospholipase A2 Activity during Chronic Anthracycline Administration

Jane McHowat, Luther M. Swift, Kimberly N. Crown and Narine A. Sarvazyan
Journal of Pharmacology and Experimental Therapeutics November 1, 2004, 311 (2) 736-741; DOI: https://doi.org/10.1124/jpet.104.069419

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCARDIOVASCULAR

Changes in Phospholipid Content and Myocardial Calcium-Independent Phospholipase A2 Activity during Chronic Anthracycline Administration

Jane McHowat, Luther M. Swift, Kimberly N. Crown and Narine A. Sarvazyan
Journal of Pharmacology and Experimental Therapeutics November 1, 2004, 311 (2) 736-741; DOI: https://doi.org/10.1124/jpet.104.069419
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • SGLT2 inhibitors and the miRNA of endothelial dysfunction
  • Optimized S-nitrosohemoglobin Synthesis in Red Blood Cells
  • Exosomal miRNAs drive thrombosis in COVID-19
Show more Cardiovascular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics